FDA Brief

Warning letters Drugs

FDA warning letter to

Jubilant HollisterStier General Partnership

High riskIssued May 28Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

What happened

FDA inspected the Kirkland, Quebec, facility from October 20 to November 3, 2025. It found sterile manufacturing design and smoke-study problems, media fills that did not simulate long interventions, discoloration on surfaces in the sterile filling area, and environmental monitoring excursions that were not investigated promptly. It also found a visible particulate investigation still open five months later while more batches were made on the same line.

What FDA found

  1. Sterile manufacturing design and airflow smoke tests did not adequately protect exposed vials from microbial contamination.

    21 CFR 211.113(b)
  2. Media fills did not simulate the longest interventions seen in commercial filling, so they did not show the process could withstand those risks.

    21 CFR 211.113(b)
  3. Discoloration on surfaces below filters and inside a filling line was not explained, and the product impact review did not check visible particulate inspection data.

    21 CFR 211.113(b)
  4. Environmental monitoring excursions, including mold on personnel, were not investigated promptly, and some non-product areas were not investigated at all.

    21 CFR 211.192
  5. A visible particulate investigation remained open five months while more batches were made on the same line without a final root cause.

    21 CFR 211.192
  6. The quality system was not effective; FDA said the quality unit lacked enough authority or did not carry out its duties.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions, including an independent contamination-risk assessment, remediation plans, and an assessment of its investigation and corrective-action systems. It also says to correct violations promptly and warns that approvals may be withheld or U.S. admission refused.

Who should pay attention

  • companies that rely on sterile drugs made at this Kirkland facility
  • quality teams at other sterile injectable manufacturers
  • U.S. supply-chain and drug-shortage planners

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  2. Sciarra Aeromed, Inc.

    Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk